Hugel held a symposium on its botulinum toxin product, Retibo, in Chengdu, China, as part of its strategy to enhance its presence in the local aesthetic medical market through training for local medical professionals.
On June 19, Hugel announced that it conducted the "Retibo Regional Symposium and Hands-On Training" in Chengdu. This event is the second in a series of regional symposiums across six Chinese cities, following a similar event in Beijing in April. Future symposiums are planned for Shanghai, Guangzhou, Hangzhou, and Wuhan.
Over 100 local medical professionals attended the event, where they learned about the clinical strengths, safety, and precise application techniques of Retibo. Ji Seung-wook, Hugel's Chief Business Officer, and Zhou Xianfeng, CEO of the Chinese partner company Shihuan Pharmaceutical, were among the key figures present, adding significance to the exchange.
Hugel, in collaboration with Shihuan Pharmaceutical, is committed to ongoing academic training for local medical professionals, promoting standardized application guidelines. Retibo has achieved over 20% market share in the Chinese toxin market, supported by its extensive market coverage and supply capabilities.
Ji Seung-wook stated, "Through continuous academic activities, we will solidify our position as a leading K-toxin company and expand our brand influence."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.